• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Recent Market Research Shows New Trends in the World Wide Pharmaceutical Market

Posted on: Wednesday, 22 November 2006, 06:00 CST

Allbizreport.com announces that new market research reports related to the Pharmaceutical industry are available to its catalog.

World Pharmaceutical Market (2007) (www.allbizreport.com/World_Pharmaceutical_Market.html)

This report provides an extensive overview of Pharmaceutical industry on a worldwide level. The report provides the authentic data on past and current performance of the Pharmaceutical industry. Not only this, it also looks closely at the various issues relevant to the Pharmaceutical industry.

- The global Pharmaceuticals Market has demonstrated consistent strong growth patterns in the last five years generating total revenues of US$ 534.8 Billion in 2005.

- Much of the growth in the Global Pharmaceutical industry can be attributed to the change in the disease profile of the global population. Increasing incidence of lifestyle related diseases have led to an increase in demand for drugs for these particular categories.

- North America remains the largest Pharmaceutical market constituting 49% of the worldwide market followed by Europe and Asia-Pacific.

- Pharmaceutical market across the world is witnessing increased opportunities in the area of Bio Pharmaceuticals, Pharmacogenomics and Biologics market.

- The smaller national markets in Asia-Pacific and Latin America are expected to grow significantly and will increase their presence in the global Pharmaceutical landscape.

The research report also addresses the issues and facts that are critical to the success of Pharmaceutical industry on a Global level.

- What are the emerging trends in the Global Pharmaceutical sector?

- What are the future prospects of the Pharmaceutical industry in various regions across the world?

- Who are the Key players in the Pharmaceutical market?

- What opportunities exist in the Pharmaceutical market?

- What Challenges are being faced by the industry?

This section provides an overview of the key financial facts and information about the prominent players in the Worldwide Pharmaceutical market like Pfizer, Johnson and Johnson, Wayeth, Merck & Co, GlaxoSmithkline and Novartis.

Pipeline Insight: Breakthrough Pain - Fast-acting players will capture majority market share (www.allbizreport.com/Pipeline_Insight_pharma_industry.html)

In spite of generic Actiq competition, Cephalon's reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016.

Discussion and quantification of the patient potential and market size of breakthrough pain in both malignant and non-malignant diseases

Assessment of the unmet clinical needs in breakthrough pain as validated by interviewed international opinion leaders

Detailed overview and assessment of key drugs in Phase II and above clinical development, including Fentora, Rapinyl, and BEMA Fentanyl

Ten-year sales forecasts to 2016 for key pipeline products

Research and analysis highlights

Relatively high unmet clinical need, additional patient groups, the launch of new products, and no further key patent expiries within the next ten years will see the breakthrough pain market more than double from 2005 to reach $2.5 billion in 2016.

As well as for oral transmucosal fentanyl products, opportunities also exist for non-oral analgesics. Intranasal and inhaled technology may provide convenient and fast acting analgesia and are potentially suitable for self-administration in the lucrative outpatient setting.

A key growth strategy will be to gain initial approval for cancer breakthrough pain and then drive sales in additional indications through off-label use or regulatory approval. Key non-malignant applications for fast acting analgesics include breakthrough pain in post-operative pain, chronic low back, and osteoarthritic pain

Mergers, acquisitions and licensing to continue drive industry growth (www.allbizreport.com/Licensing_pharma_industry_growth.html)

Inorganic growth strategies have played a significant role in the pharmaceutical industry over recent years. While acquisitions and licensing look set to continue to drive growth in the future, increasing competition for the best deal and best partner will require companies to review a broader set of potential targets and search for earlier stage licensing opportunities

A review of recent mega-mergers within the pharmaceutical industry

Analysis of the leading pharmaceutical companies increased reliance on in-licensed drugs

A brief analysis of why companies must consider earlier stage licensing opportunities

Large scale mega-mergers have shaped the competitive landscape of the leading pharmaceutical players, but analysis suggests that they may not have delivered the expected returns.

In-licensing activity has favored late stage pipeline products in the past, but increasing competition is driving the need for companies to consider early stage deals

More market research reports? Go to http://www.allbizreport.com

Source: Business Wire

More News in this Category